title: Immunovirological outcomes in 70 HIV-1-infected patients who switched to lopinavir/ritonavir after failing at least one protease inhibitor-containing regimen: a retrospective cohort study.
abstract: The immunovirological outcome of lopinavir/ritonavir was evaluated in 70 antiretroviral-experienced HIV patients; at baseline, median CD4+ cell count was 218 cells/mm(3) and median plasma viraemia 4.58 log(10) copies/mL. After 12 months, we observed an increase in CD4+ cell count to 322 cells/mm(3) (P = 0.0001) and a decrease in plasma viraemia to 2.35 log(10) copies/mL (P = 0.0001). Four patients discontinued lopinavir/ritonavir during observation. Among metabolic parameters, only triglyceride concentrations increased during treatment (P = 0.02). Twenty-six patients had a genotypic resistance test at baseline; four had > or =6 mutations known to reduce susceptibility to lopinavir/ritonavir. Undetectable plasma viraemia was obtained only in patients with < or =5 mutations (61.9%).
authors.affiliation: Institute of Infectious and Tropical Diseases, University of Milan, Luigi Sacco Hospital, via GB Grassi 74, 20157 Milan, Italy.
authors.forename: Marco
authors.initials: M
authors.lastname: Bongiovanni
authors.forename: Teresa
authors.initials: T
authors.lastname: Bini
authors.forename: Federica
authors.initials: F
authors.lastname: Tordato
authors.forename: Paola
authors.initials: P
authors.lastname: Cicconi
authors.forename: Sara
authors.initials: S
authors.lastname: Melzi
authors.forename: Dolores
authors.initials: D
authors.lastname: Repetto
authors.forename: Salvatore
authors.initials: S
authors.lastname: Sollima
authors.forename: Stefano
authors.initials: S
authors.lastname: Rusconi
authors.forename: Antonella
authors.initials: A
authors.lastname: d'Arminio Monforte
mesh_terms: D000328:Adult; D000368:Aged; D023241:Antiretroviral Therapy, Highly Active / Q000009:adverse effects; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D015658:HIV Infections / Q000188:drug therapy* / Q000276:immunology; D017320:HIV Protease Inhibitors / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D061466:Lopinavir; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D011744:Pyrimidinones / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D012189:Retrospective Studies; D019438:Ritonavir / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D017320:HIV Protease Inhibitors; D011744:Pyrimidinones; D061466:Lopinavir; D019438:Ritonavir